Photoreceptor reconstitution correlates with visual improvement after intravitreal bevacizumab treatment of choroidal neovascularization secondary to traumatic choroidal rupture.
Vitreous-Retina-Macula Consultants of New York, New York, New York 10022, USA.
Jasmine H
JH
Francis
K Bailey
KB
Freund
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002829:Choroid / Q000293:injuries*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D020419:Photoreceptor Cells, Vertebrate / Q000502:physiology*; D012421:Rupture; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab